164 related articles for article (PubMed ID: 11555513)
21. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event-A population based cohort study.
Larsson AE; Andréasson B; Holmberg H; Liljeholm M; Själander A
Eur J Haematol; 2023 Jun; 110(6):608-617. PubMed ID: 36725666
[TBL] [Abstract][Full Text] [Related]
22. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
24. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
26. Myeloproliferative syndromes and the associated risk of coronary artery disease.
Ganti AK; Potti A; Koka VK; Pervez H; Mehdi SA
Thromb Res; 2003 May; 110(2-3):83-6. PubMed ID: 12893021
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
[TBL] [Abstract][Full Text] [Related]
28. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
29. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
30. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
31. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera.
Tachibana T; Nakayama N; Matsumura A; Nakajima Y; Takahashi H; Miyazaki T; Nakajima H
Intern Med; 2017 Sep; 56(18):2487-2492. PubMed ID: 28824072
[TBL] [Abstract][Full Text] [Related]
33. Familial myeloproliferative syndrome.
Pérez-Encinas M; Bello JL; Pérez-Crespo S; De Miguel R; Tome S
Am J Hematol; 1994 Jul; 46(3):225-9. PubMed ID: 8192153
[TBL] [Abstract][Full Text] [Related]
34. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Gilbert HS
Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
[TBL] [Abstract][Full Text] [Related]
36. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B
J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
[TBL] [Abstract][Full Text] [Related]
37. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
38. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
39. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.
Basquiera AL; Soria NW; Ryser R; Salguero M; Moiraghi B; Sackmann F; Sturich AG; Borello A; Berretta A; Bonafé M; Barral JM; Palazzo ED; García JJ
Hematology; 2009 Dec; 14(6):323-30. PubMed ID: 19941738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]